Perspective Therapeutics, Inc. CATX
Set alert
1.06 USD -0.09 -7.48%
As of Nov 2, 2:13 PM ET
1.06 Day range 1.19
1.06 52-week range 6.16
- YTD
- -61.31%
- 1 year
- -61.03%
- Open
- 1.15
- Prev close
- 1.15
- Mkt cap
- 121.57M
- Vol
- 1.34M
- Avg vol
- 2.04M
- EPS
- -1.33
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.06
- High
- 1.19
- Forward P/E
- -2.91
- Beta
- 1.47
- Short ratio
- 4.69
- Inst. own
- 81.43%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 7.97
- 200-d avg
- 12.20
- 1y target
- 16.15
5Y chart
Events in this range
- Jun 17, 2024Split: 1 for 10
- Oct 11, 2024Rating: Oppenheimer · Outperform → Outperform
- Oct 24, 2024Rating: UBS · — → Buy
- Oct 24, 2024Rating: Wedbush · Outperform → Outperform
- Nov 22, 2024Rating: Oppenheimer · Outperform → Outperform
- Nov 25, 2024Downgrade: B of A Securities · Buy → Neutral
- Nov 25, 2024Rating: RBC Capital · Outperform → Outperform
Signals (70)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 19, 2026 | 2 weeks ago |
| SMA: Bearish | Sep 7, 2026 | 1 month ago |
| SMA: Bullish | Aug 10, 2026 | 2 months ago |
| SMA: Bearish | Jul 6, 2026 | 3 months ago |
| SMA: Bullish | Jun 29, 2026 | 4 months ago |
| SMA: Bearish | Jun 1, 2026 | 5 months ago |
| MACD: Sell Signal | Apr 27, 2026 | 6 months ago |
| SMA: Bearish | Mar 23, 2026 | 7 months ago |
| RSI: Overbought | Feb 16, 2026 | 8 months ago |
| SMA: Bullish | Jan 26, 2026 | 9 months ago |
| SMA: Bullish | Jan 19, 2026 | 9 months ago |
| SMA: Bearish | Jan 12, 2026 | 9 months ago |
| MACD: Buy Signal | Dec 29, 2025 | 10 months ago |
| SMA: Bullish | Dec 15, 2025 | 10 months ago |
| MACD: Sell Signal | Nov 3, 2025 | 12 months ago |
| SMA: Bearish | Oct 20, 2025 | 1 year ago |
| SMA: Bearish | Oct 20, 2025 | 1 year ago |
| SMA: Bullish | Sep 29, 2025 | 1 year ago |
| SMA: Bearish | Aug 4, 2025 | 1 year ago |
| SMA: Bullish | Jun 2, 2025 | 1 year ago |
| SMA: Bullish | Apr 21, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 3, 2025 | 1 year ago |
| RSI: Oversold | Feb 17, 2025 | 1 year ago |
| SMA: Bearish | Jan 27, 2025 | 1 year ago |
| SMA: Bullish | Jan 20, 2025 | 1 year ago |
| RSI: Oversold | Jan 13, 2025 | 1 year ago |
| RSI: Oversold | Nov 18, 2024 | 1 year ago |
| SMA: Bearish | Sep 16, 2024 | 2 years ago |
| SMA: Bearish | Sep 16, 2024 | 2 years ago |
| MACD: Sell Signal | Sep 16, 2024 | 2 years ago |
| MACD: Buy Signal | Aug 26, 2024 | 2 years ago |
| SMA: Bullish | Aug 12, 2024 | 2 years ago |
| SMA: Bearish | Aug 5, 2024 | 2 years ago |
| SMA: Bullish | Jul 8, 2024 | 2 years ago |
| SMA: Bullish | Jul 1, 2024 | 2 years ago |
| SMA: Bearish | Jun 17, 2024 | 2 years ago |
| MACD: Sell Signal | Jun 3, 2024 | 2 years ago |
| SMA: Bearish | May 20, 2024 | 2 years ago |
| RSI: Overbought | Jan 29, 2024 | 2 years ago |
| SMA: Bullish | Jan 1, 2024 | 2 years ago |
| SMA: Bullish | Dec 11, 2023 | 2 years ago |
| MACD: Buy Signal | Dec 11, 2023 | 2 years ago |
| RSI: Oversold | Sep 11, 2023 | 3 years ago |
| SMA: Bearish | Aug 7, 2023 | 3 years ago |
| SMA: Bearish | Jul 24, 2023 | 3 years ago |
| MACD: Sell Signal | Jul 10, 2023 | 3 years ago |
| MACD: Buy Signal | Jun 19, 2023 | 3 years ago |
| SMA: Bullish | Jun 12, 2023 | 3 years ago |
| MACD: Sell Signal | May 22, 2023 | 3 years ago |
| SMA: Bearish | May 15, 2023 | 3 years ago |
| RSI: Overbought | Mar 13, 2023 | 3 years ago |
| SMA: Bullish | Jan 30, 2023 | 3 years ago |
| SMA: Bullish | Jan 30, 2023 | 3 years ago |
| MACD: Buy Signal | Jan 30, 2023 | 3 years ago |
| MACD: Sell Signal | Dec 19, 2022 | 3 years ago |
| SMA: Bearish | Dec 5, 2022 | 3 years ago |
| SMA: Bullish | Nov 14, 2022 | 3 years ago |
| SMA: Bullish | Nov 14, 2022 | 3 years ago |
| MACD: Buy Signal | Nov 14, 2022 | 3 years ago |
| MACD: Sell Signal | Oct 31, 2022 | 4 years ago |
| SMA: Bearish | Oct 24, 2022 | 4 years ago |
| SMA: Bullish | Oct 3, 2022 | 4 years ago |
| SMA: Bullish | Oct 3, 2022 | 4 years ago |
| MACD: Buy Signal | Oct 3, 2022 | 4 years ago |
| MACD: Sell Signal | Sep 26, 2022 | 4 years ago |
| SMA: Bearish | Sep 19, 2022 | 4 years ago |
| SMA: Bullish | Aug 1, 2022 | 4 years ago |
| SMA: Bullish | Jul 4, 2022 | 4 years ago |
| RSI: Oversold | Jun 13, 2022 | 4 years ago |
| SMA: Bullish | Mar 21, 2022 | 4 years ago |
Key statistics
- Market cap
- 212.22M
- Enterprise value
- -70.95M
- Trailing P/E
- 0.00
- Forward P/E
- -2.91
- PEG ratio
- 0.00
- Price / sales
- 136.30
- Price / book
- 0.65
- EPS (TTM)
- -1.33
- Beta
- 1.47
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 1.56M
- Revenue growth
- 33.70%
- Free cash flow
- -49.49M
- Total cash
- 267.85M
- Total debt
- 4.27M
- Return on equity
- -27.02%
- Shares outstanding
- 67.59M
- Short % of float
- 18.81%
- 50-day average
- 7.97
- 200-day average
- 12.20
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 16.15 +1417.9% upside
Now 1.06
- Target (low)
- 6.00
- Target (mean)
- 16.15
- Target (high)
- 21.00
Ratings (0m) 10 9 buy · 1 hold · 0 sell
- Strong buy1
- Buy8
- Hold1
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.25994.
Financials — quick view
CATX Revenue — quarterly 81.00K
CATX Net income — quarterly -26.79M
CATX EPS — quarterly -0.22
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 25, 2024 | RBC Capital | main | Outperform | Outperform |
| Nov 25, 2024 | B of A Securities | down | Buy | Neutral |
| Nov 22, 2024 | Oppenheimer | main | Outperform | Outperform |
| Oct 24, 2024 | Wedbush | reit | Outperform | Outperform |
| Oct 24, 2024 | UBS | init | — | Buy |
| Oct 11, 2024 | Oppenheimer | reit | Outperform | Outperform |
About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- perspectivetherapeutics.com
News
- RBC Capital Downgrades Perspective Therapeutics to Sector Perform, Lowers Price Target to $4
- Perspective Therapeutics Posts 72% 18-Month PFS in VMT-α-NET Study Update
- Perspective Therapeutics Announces Interim Data From Its Current Phase 1/2a Clinical Study Of [212Pb]VMT-α-NET In Patients With Unresectable Or Metastatic Somatostatin Receptor Type 2 Expressing Neuroendocrine Tumors At ESMO Congress 2026
- Perspective's [212Pb]Bamzireotide Navoxetan (VMT-α-NET) Demonstrates Encouraging Safety, Durable Disease Control, and Robust Tumor Response Across Multiple Dose Cohorts in Phase 1/2a Trial in Advanced SSTR2-Expressing NETs
- Perspective Therapeutics Receives FDA Fast Track Designation For Development Of PSV359 For Adult Patients With Locally Advanced Unresectable And/Or Metastatic Fibroblast Activation Protein-Positive Solitary Fibrous Tumors
- Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors
- Perspective Therapeutics (NYSEAMERICAN:CATX) Given “Buy” Rating at BTIG Research
- BTIG Reiterates Buy on Perspective Therapeutics, Maintains $14 Price Target
- Perspective Therapeutics Announces Acceptance of [212Pb]VMT-α-NET Data for Presentation at the NANETS 2026 Multidisciplinary NET Medical Symposium
- Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Stock Now Rated “Buy” by Sell-Side Analysts
Your note
Sign in to keep a note on CATX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AUSTIN MARK JOHN | Chief Financial Officer | Conversion of Exercise of derivative security | Apr 22, 2024 | 84,030 |
| HENSON HEIDI | Director | Purchase | Dec 3, 2024 | 0 |
| HUNT JONATHAN ROBERT | Chief Financial Officer | Purchase | Nov 24, 2024 | 48,800 |
| LANTHEUS ALPHA THERAPY, LLC | Beneficial Owner of more than 10% of a Class of Security | Purchase | Mar 5, 2024 | 0 |
| PUHLMANN MARKUS | Officer | Purchase | Jan 23, 2024 | 1,375,420 |
| SPOOR JOHAN M | Chief Executive Officer | Purchase | Dec 3, 2024 | 55,257 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 8.14% | 5,504,822 | 17.29M | Sep 29, 2024 |
| Janus Henderson Group PLC | 7.10% | 4,799,352 | 15.07M | Sep 29, 2024 |
| Blackrock Inc. | 5.98% | 4,039,974 | 12.69M | Sep 29, 2024 |
| Avidity Partners Management, LP | 5.10% | 3,444,002 | 10.81M | Sep 29, 2024 |
| Commodore Capital Lp | 4.96% | 3,350,000 | 10.52M | Sep 29, 2024 |
| Vanguard Group Inc | 4.55% | 3,076,941 | 9.66M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.50% | 1,692,046 | 5.31M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.06% | 1,393,938 | 4.38M | Oct 30, 2024 |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 1.72% | 1,162,536 | 3.65M | Sep 29, 2024 |
| Fidelity Advisor Biotechnology Fund | 1.56% | 1,052,713 | 3.31M | Oct 30, 2024 |
| Janus Henderson Global Life Sciences Fund | 1.41% | 953,832 | 3.00M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.19% | 806,419 | 2.53M | Sep 29, 2024 |